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Abstract
Introduction Previous research has shown that heavy
cannabis users develop tolerance to the impairing effects
of Δ9-tetrahydrocannabinol (THC) on neurocognitive
functions. Animal studies suggest that chronic cannabis
consumption may also produce cross-tolerance for the
impairing effects of alcohol, but supportive data in humans
is scarce.
Purpose The present study was designed to assess toler-
ance and cross-tolerance to the neurocognitive effects of
THC and alcohol in heavy cannabis users.
Methods Twenty-one heavy cannabis users participated in a
double-blind, placebo-controlled, three-way study. Subjects
underwent three alcohol-dosing conditions that were
designed to achieve a steady blood alcohol concentration
of about 0, 0.5, and 0.7 mg/ml during a 5-h time window.
In addition, subjects smoked a THC cigarette (400 μg/kg)
at 3 h post-onset of alcohol dosing during every alcohol
condition. Performance tests were conducted repeatedly
between 0 and 7 h after onset of drinking and included
measures of perceptual motor control (critical tracking
task), dual task processing (divided-attention task), motor
inhibition (stop-signal task), and cognition (Tower of
London).
Results Alcohol significantly impaired critical tracking,
divided attention, and stop-signal performance. THC
generally did not affect task performance. However,
combined effects of THC and alcohol on divided attention
were bigger than those by alcohol alone.
Conclusion In conclusion, the present study generally
confirms that heavy cannabis users develop tolerance to
the impairing effects of THC on neurocognitive task
performance. Yet, heavy cannabis users did not develop
cross-tolerance to the impairing effects of alcohol, and the
presence of the latter even selectively potentiated THC
effects on measures of divided attention.
Keywords THC.Alcohol.Tolerance.Impulsivity.
Cognition.Performance
Introduction
Cannabis use is largely concentrated among young people,
aged 15–34 years. Population data suggest that, on average,
31% of young Europeans have ever used cannabis, while
12.5% have used the drug in the last year (EMCCDA
2009). In the USA, lifetime prevalence of cannabis use
among young adults and last year prevalence are 49% and
21%, respectively (DHHS/SAMHSA 2007). Prospective
studies have demonstrated that despite spontaneous cessa-
tion of cannabis use in the majority of cannabis users, a
substantial proportion of users develop stable use patterns
characterized by continuous use of cannabis (Chen and
Kandel 1995; Perkonigg et al. 2008; Perkonigg et al. 1999).
It has been estimated that over 1% of all European adults,
about 4 million, are using cannabis daily or almost daily.
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Previous research has demonstrated that daily cannabis
users are less sensitive to the impairing effects of Δ9-
tetrahydrocannabinol (THC) intoxication on cognitive and
psychomotor functions (D'Souza et al. 2008; Hart et al.
2001; Jones et al. 1981; Ramaekers et al. 2009) that have
often been demonstrated in occasional cannabis smokers
(Curran et al. 2002; Hart et al. 2002; Heishman et al. 1989;
Lamers and Ramaekers 2001; Ramaekers et al. 2004;
Ramaekers et al. 2006a), even when THC concentrations
and levels of subjective high are similar (Ramaekers et al.
2009). This loss of sensitivity or tolerance to the behavioral
effects of THC after prolonged use is believed to result
from a change in pharmacodynamic response as evinced by
CB1 receptor downregulation in large parts of the brain
(Gonzalez et al. 2005). Alternatively, it has also been
suggested that heavy cannabis users recruit alternative
neural networks as a compensatory mechanism during task
performance. Eldreth et al. (2004) and Kanayama et al.
(2004) showed that compared with controls, cannabis users
utilized additional brain regions to perform cognitive tasks,
i.e., they compensated by working harder and recruiting
compensatory networks.
Animal research has also suggested that pharmacological
tolerance to the effects of THC may lead to cross-tolerance
for actions of other drugs. Repeated cannabinoid adminis-
tration decreased responsiveness of dopamine neurons in
the mesoaccumbens in adolescent rats to an acute challenge
with cannabinoid agonists but also to challenges with
morphine, cocaine, and amphetamine (Pistis et al. 2004).
The cannabinoid system has also been indicated in the
development of tolerance to the effects of ethanol. Chronic
ethanol exposure has been shown to produce downregula-
tion of CB1 receptors and altered CB1 receptor gene
expression (Hungund and Basavarajappa 2000; Ortiz et al.
2004). Rats made tolerant to the depressant effects of THC
were also tolerant to the behavioral depressant effects of
ethanol (Newman et al. 1972). Rats made tolerant to either
ethanol or THC exhibited cross-tolerance to effects of the
opposite compounds in learning and performance tasks
(Siemens and Doyle 1979; Sprague and Craigmill 1976).
These data strongly suggest the possibility of cross-
tolerance between ethanol and THC.
Ethanol and THC share many similarities in their
actions. Pharmacological and behavioral effects of ethanol,
such as hypothermia, euphoria, analgesia, sedation, and
cognitive and motor dysfunction have also been demon-
strated for THC (Ameri 1999; Iversen 2003). Combined use
of ethanol and THC in occasional cannabis users has
repeatedly been shown to increase the magnitude of
cognitive and motor impairments in an additive manner
(Lamers and Ramaekers 2001;L i g u o r ie ta l .2002;
Ramaekers et al. 2004). It is unclear however if combined
use of ethanol and cannabis would also lead to similar
impairments in these performance domains in heavy
cannabis users. Based on the animal literature, it might be
expected that heavy users of cannabis may develop
tolerance to the impairing effects of THC, ethanol, and
their combination. However, there is only little research in
humans to support this claim. A few studies have reported
(Casswell and Marks 1973; Marks and MacAvoy 1989;
Wright and Terry 2002) that regular cannabis users were
less impaired in peripheral signal detection and tracking
accuracy than controls while intoxicated by THC and/or
ethanol. These finding suggest either the development of
tolerance and cross-tolerance in regular cannabis users, or
their ability to compensate for intoxication effects.
The present study was designed to assess the effects of
THC and alcohol, alone, and in combination, on neuro-
cognitive performance of heavy cannabis users in order to
establish the presence of tolerance or cross-tolerance to the
impairing effects of THC and ethanol. Neurocognitive tasks
were selected from previous studies demonstrating their
sensitivity to measure THC-induced impairments in occa-
sional cannabis users (Ramaekers et al. 2009; Ramaekers et
al. 2006b).
Methods
Subjects
Twenty-one heavy cannabis users (15 males, 6 females)
entered the present study. A summary of their demograph-
ics and history of drug use is given in Table 1. Subjects
were recruited through advertisements in coffee shops.
Initial screening comprised of a questionnaire on medical
history. Subjects were examined by the medical supervisor
who checked vital signs and took blood and urine samples.
Standard blood chemistry, hematology, and drug screen
tests were conducted on these samples. General inclusion
criteria were: free from psychotropic medication; good
physical health as determined by medical examination and
laboratory analysis; absence of any major medical, endo-
crine, and neurological condition; normal weight, body
mass index (weight per square length) between 18 and
28 kg/m
2; and written informed consent. Specific inclusion
criteria were frequent use of cannabis (smoking on more
than 4 days/week) during the previous year and presence of
THC in serum on the day of screening. Exclusion criteria
were: history of drug abuse (excluding marijuana) as
assessed by drug urine screens and questionnaires; no
experience with alcohol; non cigarette smokers; pregnancy
or lactation or failure to use reliable contraceptives; color
blindness, excessive drinking (>25 standard alcoholic
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systolic >170) or history of psychiatric disorders.
The study was conducted according to the code of
ethics on human experimentation established by the
declaration of Helsinki (1964) and amended in Seoul
(2008). All subjects were fully informed of study
procedures, adverse reactions to drug treatments, legal
rights and responsibilities, expected benefits of a general
scientific nature, and their right for voluntary termination
without penalty or censure. A permit for obtaining,
storing, and administering marijuana was obtained from
the Dutch drug enforcement administration.
Design, doses, and administration
The study was conducted according to a double-blind,
placebo-controlled, three-way design. Subjects underwent
three alcohol-dosing conditions that were designed to
achieve steady state blood alcohol concentration (BACs)
of about 0, 0.5, and 0.7 mg/ml during a 5-h time window.
The order of alcohol-dosing conditions was counterbal-
anced across subjects. In addition, subjects smoked a THC
cigarette (400 μg/kg) at 3 h post-onset of alcohol dosing, in
each alcohol condition. Alcohol dosing started at
10:30 hours in the morning with placebo alcohol, 0.5 or
0.7 g/kg alcohol. Additional alcohol booster doses of about
0.1 g/kg or alcohol placebo were given on an as needed
basis at approximately every half hour up until 4.5 h after
onset of alcohol dosing in order to keep BAC at the desired
level. On average, subjects received 5.4 additional booster
doses containing alcohol. Alcohol was administered as
“pure” ethanol (96%) mixed with orange juice to a volume
of 300 ml for the initial dose. Total volumes of booster
doses mixed with orange juice were approximately 80 ml.
THC smoking started at 3 h post-onset of alcohol dosing
and lasted for about 15 min. The cigarettes were prepared
beforehand for each individual from stock provided by the
Dutch Bureau for Medicinal Cannabis. Marijuana cigarettes
were prepared from batches containing 11% THC, a
standard potency for marijuana sold at Dutch pharmacies
for medical use. The total amount of cannabis was weight
calibrated for each individual subject and mixed with
tobacco to achieve a standard cigarette size and weight.
Subjects were instructed to smoke the cigarette according to
a standardized procedure (Ramaekers et al. 2006a) in order
to minimize the subject's possibility of dose titration and to
increase optimal absorption of THC: i.e., inhale for 4 s,
hold breath for 10 s, and exhale/break for 15 s. This
sequence was repeated until the cigarettes were smoked
as completely as possible. Mean (SD) number of puffs
smoked from the cigarette in the three alcohol/THC
conditions were 17 (4.4), 17 (5.2), and 17 (2.9)
respectively. A minimum wash-out of 4 days transpired
between experimental treatments.
Procedures
Subjects were asked to refrain from drugs other than
cannabis. Subjects were not allowed to use alcohol on the
day prior to an experimental session and were requested to
arrive at experimental sessions well rested. Subjects were
allowed to continue their usual cannabis-smoking routine
during the study period. Drug and alcohol screens were
performed prior to experimental sessions upon arrival of the
subject. Urine drug screens assessed for the presence of
morphine, cocaine, marijuana, methampethamine, and
amphetamine. Alcohol/THC treatments were only adminis-
tered if subjects tested positive for THC, but negative for
other drugs and alcohol. Subjects always tested positive for
THC on test days. Subjects received a standardized lunch
prior to THC smoking. Performance tests were conducted at
fixed intervals during 7 h post-onset of alcohol dosing. The
critical tracking task was conducted at 1 h, 2 h, 3 h20, 4 h
20 min, 5 h 20 min and 6 h 20 min post-onset of alcohol
administration; a divided-attention task was conducted at
1 h 10 min, 3 h 30 min, 4 h 30 min and 5 h 30 min post-
onset alcohol dosing; the stop-signal task was conducted at
1 h 30 min, 4 h and 6 h post-onset alcohol dosing; and a
Table 1 Subject characteristics (mean, SD) and history of drug use
for heavy cannabis users that completed the study (N=19)
Demographic variables
Age (years) 23.2 (8.4)
Age range (years) 19–38
Frequency of cannabis use/number of times per year 373.7 (101.6)
Joints per occasion (number) 5.0 (3.9)
History of cannabis use (years) 9.0 (5.5)
Frequency of alcohol use/number of times per year 76.7 (50.6)
Drinks per occasion 8.4 (5.7)
History of alcohol use (years) 9.8 (3.1)
Occasional use of other drugs (number of subjects)
MDMA 12
Amphetamine 6
Cocaine 10
LSD 1
Mushrooms 8
Salvia 1
Combined use of THC and alcohol (number of
subjects)
18
Number of subjects attesting to driving under the
influence of cannabis (DUIC)
15
Frequency of DUIC/year 139.5 (172.9)
Number of subjects attesting to driving under the
influence of cannabis and alcohol (DUICA)
6
Frequency of DUICA/year 11.5 (9.2)
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10 min and 6 h 10 min post-onset of alcohol dosing.
Subjects received a training session prior to onset of the
experimental sessions in order to familiarize them with the
tests and procedures and minimize practice effects.
Neurocognitive assessments
The critical tracking test (CTT) measures the subject's
ability to control a displayed error signal in a first-order
compensatory tracking task. Error is displayed as a
horizontal deviation of a cursor from the midpoint on a
horizontal, linear scale. Compensatory joystick movements
null the error by returning the cursor to the midpoint. The
subject's compensatory response increases in frequency
with an increasing phase lag. Control is lost at the point
where the compensatory response lags the cursor's last
movement by 180°. The response frequency at this point is
defined as the critical frequency or lambda-c. The test
includes five trials of which the lowest and the highest
score are removed. The average of the remaining scores is
taken as the final score (Jex et al. 1966)
The divided-attention task (DAT) measures the sub-
ject's ability to divide attention between two tasks
performed simultaneously. The primary task consists of
the tracking task as described above but at a constant level
of difficulty set at 50% of the subject's maximum capacity.
Tracking error is measured as the difference in millimeters
between the position of the cursor and the midpoint of the
scale. In the secondary task, the subject monitors a central
display upon which single digits are presented at 1-s
intervals. The occurrence of the digit “2” is a signal for the
subject to remove the foot from a pedal as rapidly as
possible. Inter stimulus interval varies between 1 and 2 s.
Mean absolute tracking error (millimeters) and number of
control losses are the main parameters of the primary task.
Number of correct signal detections and reaction time to
signals are the main performance measures in the
secondary task (Moskowitz 1973).
The stop-signal task (SST) measures motor impulsivity,
which is defined as the inability to inhibit an activated or
pre-cued response leading to errors of commission. The
current test is adapted from an earlier version of Fillmore et
al. (Fillmore et al. 2002) and has been validated for
showing stimulant and sedative drug effects (Ramaekers
and Kuypers 2006). The task requires subjects to make
quick key responses to visual go signals, i.e., the letters
ABCD presented one at a time in the middle of the screen,
and to inhibit their response if a subsequent visual stop
signal, i.e., “*”, appears in one of the four corners of the
screen. The stop signal is presented at predefined delays of
50, 150, 250, and 350 msec. The main parameters are stop
reaction time and commission errors during “no go” trials.
Stop reaction time represents the estimated mean time
required to inhibit a response. Stop reaction time is
calculated by subtracting the stop-signal delay from the
reaction time on go-trials associated with nth percentile of
the reaction time distribution. The nth percentile corre-
sponds to the percentage of commission errors (Logan et al.
1984)
The Tower of London (TOL) is a decision-making task
that measures executive function and planning (Shallice
1982). The original version of the Tower of London
consists of three colored balls, which must be arranged on
three sticks to match the target configuration on a picture
while only one ball can be moved at a time. The present
version consists of computer-generated images of begin-
and end-arrangements of the balls. The subject decides as
quickly as possible, whether the end-arrangement can be
accomplished in 2, 3, 4, or 5 steps from the begin
arrangement by pushing the corresponding coded button.
Number of correct decisions and mean reaction time are the
main outcome measures.
Subjective high and drunkenness
Subjects rated their subjective high and drunkenness on
visual analogue scales (100 mm) as a percentage of the
maximum “high” or “drunkenness” ever experienced.
Subjective high and drunkenness were rated on nine
consecutive time points throughout 8 h after onset alcohol
dosing. In addition, subject rated which of the two drugs
(ethanol or THC) produced the most dominant feeling at
each of these time points.
Pharmacokinetic assessments
Blood samples (6 ml) were taken at baseline, 15, 30,
45, and 60 min during the first hour after onset of THC
smoking (THC cigarette was smoked within 15 min)
a n ds u b s e q u e n t l ya te v e r y3 0m i nb e t w e e n1a n d4h
after smoking. Blood samples were centrifuged and
serum was frozen at −20°C until analyses for pharma-
cokinetic assessments. THC concentrations and its main
metabolites (THC-COOH, OH-THC) were determined
using a validated and accredited routine method for the
analysis of cannabinoids in forensic blood samples
(Toennes et al. 2008). The procedure essentially consists
of an automated solid phase extraction and gas chroma-
tography with mass spectrometric detection with a limit of
quantification of 0.6 ng/ml which has also been success-
fully used for the analysis of THC in oral fluid (Kauert et
al. 2006; Toennes et al. 2010). Subjects' BAC was
monitored using a Lion SD4 breath alcohol analyser at
baseline and approximately every 30 min through 8 h after
onset of alcohol dosing.
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All neurocognitive measures were analyzed with SPSS 13.0
using a GLM univariate analysis of variance with Alcohol
(three levels) and THC over time (three to six levels,
depending on the number of test repetitions) as fixed factors
and Subjects as random factor. The univariate model tested
for main effects of alcohol, THC over time, and alcohol×
THC over time. The factor alcohol compares performance
between three alcohol doses across all test replications and
gives an indication of the overall effect of alcohol on
performance. The factor THC over time compares perfor-
mance before and after THC smoking across all alcohol
conditions and gives an indication of the overall THC effect
on performance. The interaction alcohol×THC indicates
whether the effect of THC on performance changes as a
function of alcohol dose. Subjective measures of high and
drunkenness were analyzed according to the same statistical
design but tested only for the main effects of THC over
time (nine levels) and alcohol (three levels), respectively.
Results
Missing values
Two subjects dropped out of the study after the first
treatment condition for reasons unrelated to the study.
Incomplete data from the drop-out subject did not enter
statistical analysis. One subject was unable to reliably
perform the divided-attention task. His data were not
included in the statistical analysis of this task.
BAC and THC concentrations
Mean (SE) BAC concentrations and THC concentrations
during treatments are shown in Fig. 1 and Table 2,
respectively. On average, BAC concentration achieved the
desired peak levels of 0.5 and 0.7 mg/ml in the low and
high alcohol dose conditions. BAC levels dipped around
2.5 h after onset of dosing during lunch when subjects did
not receive a booster dose, but returned to peak levels after
administration of subsequent booster doses. BACs during
the alcohol placebo condition were always zero. Concen-
trations of THC and its main metabolites were comparable
in every treatment condition. Seven subjects indicated that
they had smoked a cannabis cigarette on test days prior to
the test session. All other subjects experienced their last
cannabis cigarette during the preceding day. The impact of
routine cannabis smoking of subjects was negligible since
average baseline THC levels were low (i.e., <10 ng/mL) as
compared to THC levels after smoking the experimental
THC cigarette.
Subjective high and drunkenness
Subjective high was significantly elevated by the factor THC
(F8,462=64.7; p=0.000). Subjective drunkenness was signif-
icantly elevated by alcohol (F8,462=86.6;p=0.000).Subjects
indicated that the feeling of drunkenness was dominant prior
to THC smoking and that the feeling of high was dominant
after smoking. Mean (SE) rating of subjective high,
drunkenness, and dominance of drug are shown in Fig. 2.
Neurocognitive measures
Lambda-c in the critical tracking task significantly de-
creased after alcohol (F2,303=5.42; p=0.005) but was not
affected by THC or alcohol×THC. Mean (SE) lambda-c in
every treatment condition is shown in Fig. 3.
Alcohol also significantly increased tracking error,
control losses, and reaction time (F2,185=6.68, 9.51, and
16.91, respectively; p<0.002) and decreased the number of
correct signal detections (F2,185=7.6; p=0.001) in the
divided-attention task. In addition, number of control
losses, correct signal detections, and reaction time were
also significantly affected by THC (F3,185=5.97, 6.89, and
9.46, respectively; p<0.001). Control losses were also
affected by the interaction of alcohol×THC (F6,185=2.31;
p=0.036). Mean (SE) performance in the divided-attention
task in every treatment condition is shown in Fig. 4.
Stop reaction time (F2,141=4.03; p=.020) and commis-
sion errors (F2,141=7.51; p=0.001) in the stop-signal task
significantly increased after alcohol, but were unaffected by
THC or alcohol×THC. Performance in the Tower of
London task was not affected by any factor. Mean (SE)
performance in the stop-signal task in very treatment
condition is shown in Fig. 5.
Discussion
The present study was designed to assess tolerance and
cross-tolerance to the neurocognitive effects of THC and
alcohol in heavy cannabis users. Results demonstrated that
alcohol detrimentally affected performance of heavy can-
nabis users. THC generally did not affect performance,
confirming earlier reports on tolerance to performance
impairing effects of THC. Performance in the divided-
attention task however was affected by both THC and
alcohol, and their combination.
Alcohol was given in a low- and high-dose condition
with the general aim to achieve steady BAC concentrations
around 0.5 and 0.7 mg/ml, respectively, during performance
testing in a 5-h time window. After 5 h, BACs were
allowed to decline over time. Steady BACs were achieved
by administering booster alcohol doses almost every 30 min
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produced the desired BAC concentrations during perfor-
mance testing in the two alcohol conditions. Performance
tests were basically scheduled in three separate time
windows: i.e., between 1–2.5, 3.5–5.5, and 5.5–7 h after
alcohol onset. Mean BAC concentrations in the low and
high alcohol-dose condition fluctuated around 0.5 and
0.7 mg/ml, respectively, during performance testing in the
first and second time window. Performance testing during
the third time window took place during the declining
phase of BAC in both alcohol conditions. Subjective
feelings of drunkenness during alcohol treatments were
also comparable during the first and second time window,
and gradually decreased with declining BACs in the third
time window. BAC and subjective drunkenness data
indicate that the levels of alcohol intoxication were
comparable during performance testing in the first and
second time window (i.e., prior and post-smoking THC),
Table 2 Mean (SD) serum concentrations of THC, THC-COOH, and OH-THC as a function of time after onset of smoking
Time after smoking (h)
Baseline 0.25 0.5 0.75 1 1.5 2 2.5 3 3.5 4
Alcohol placebo
THC Mean 8.6 112.1 49.3 32.0 24.7 20.7 13.4 10.1 8.8 8.6 7.9
SD 10.3 47.5 21.9 12.2 8.9 6.7 6.4 4.4 4.1 4.5 6.2
THC-COOH Mean 80.7 124.0 123.9 111.8 109.7 106.5 102.0 97.7 87.0 82.7 80.6
SD 75.1 102.4 104.6 91.3 91.8 90.4 84.9 86.7 74.3 64.7 67.0
OH-THC Mean 4.9 16.3 14.4 12.0 10.8 9.4 7.5 6.1 5.3 5.0 4.8
SD 7.1 10.0 10.0 7.8 6.8 5.5 4.6 4.4 3.8 3.9 3.8
Low alcohol dose
THC Mean 9.0 98.3 47.7 31.2 23.1 19.5 14.4 10.7 7.8 8.6 8.0
SD 11.8 50.0 28.0 19.1 13.2 12.2 9.2 7.4 5.1 6.3 6.0
THC-COOH Mean 58.6 82.9 83.7 79.0 75.7 76.3 70.4 65.6 52.3 57.3 54.0
SD 53.4 61.0 58.8 56.1 59.5 63.5 55.2 54.5 48.7 49.7 50.2
OH-THC Mean 4.5 18.4 15.2 12.6 10.6 9.8 7.7 6.1 4.7 5.0 4.3
SD 7.0 13.6 9.3 7.3 6.5 6.1 5.2 4.3 3.9 4.4 3.6
High alcohol dose
THC Mean 9.6 93.0 45.2 27.1 18.5 16.0 11.6 10.0 7.9 8.4 8.1
SD 15.7 40.5 26.7 14.2 8.6 7.8 6.3 5.9 5.1 5.4 6.0
THC-COOH Mean 70.3 87.9 96.7 94.2 85.8 73.1 71.0 68.8 62.9 60.1 62.3
SD 61.7 62.9 75.3 76.6 72.5 63.2 62.6 62.2 56.4 49.6 50.2
OH-THC Mean 5.8 17.8 16.1 12.8 10.8 8.8 7.3 6.5 5.2 5.2 4.8
SD 9.5 10.0 9.4 7.7 7.3 5.8 5.2 4.8 4.1 4.0 3.9
Fig. 1 Mean (SE) BAC as a
function of time after onset of
alcohol drinking and onset of
THC cigarette smoking in the
low- and high-dose alcohol
condition. Arrows indicate time
points at which booster alcohol
doses could be administered
on an as needed basis to achieve
steady BAC levels between 1
and 5 h after onset of drinking
396 Psychopharmacology (2011) 214:391–401and declined at similar rates during performance assess-
ments in the third time window.
The effects of alcohol in objective performance measures
were consistent and straightforward. Alcohol significantly
affected all performance measures in the critical tracking
task, the divided-attention task, and the stop-signal task. In
the critical tracking task, alcohol significantly decreased
tracking performance. In the divided-attention task, alcohol
increased reaction time, number of control losses, and
decreased number correct signal detections and tracking.
Alcohol increased stop reaction time and commission errors
in the stop-signal task. The neurocognitive effects of
alcohol in heavy cannabis users are comparable to those
that have been reported in earlier studies in infrequent drug
Fig. 3 Mean (SE) lambda-c in
theCTTasafunctionoftimeafter
alcohol and THC administration
in every treatment condition
Fig. 2 Mean (SE) subjective
high (lower panel) and drunk-
enness (middle panel)a sa
function of time after alcohol
and THC administration. The
upper panel displays subjective
dominance of alcohol or THC
over time
Psychopharmacology (2011) 214:391–401 397(including cannabis) users (Heishman et al. 1988; Kuypers
et al. 2006; Liguori et al. 2002; Ramaekers and Kuypers
2006) and healthy volunteers (de Wit et al. 2000;
Vermeeren et al. 2002). The present data strongly indicate
that heavy cannabis use does not produce cross-tolerance to
the impairing potential of alcohol.
Subjects smoked a cannabis cigarette every treatment
condition at 3 h after onset of alcohol or alcohol placebo
administrations. Subjective high was elevated to similar
degrees after smoking cannabis in each treatment condition.
THC concentrations were also comparable between treat-
ments with peak THC concentrations ranging from 93 to
112 ng/ml. Together, these data suggest that THC admin-
istrations were very comparable in every treatment condition.
THC did not affectperformance of heavy cannabisusers in
thecriticaltrackingtask,thestop-signaltask,andtheTowerof
London. These tasks have previously been shown to be very
sensitivetotheimpairingpotentialofTHCwhenadministered
to infrequent cannabis (Ramaekers et al. 2006a). The lack of
THC effects on any of these tasks basically confirms
previous notions that heavy cannabis users can develop
tolerance to behaviorally impairing effects of THC (D'Souza
et al. 2008;H a r te ta l .2001; Jones et al. 1981;R a m a e k e r se t
al. 2009). However it was interesting to note that tolerance
was not apparent in all performance tasks. During divided-
attention task performance, THC increased the number of
control losses and reaction time and decreased the number of
Fig. 5 Mean (SE) stop reaction time and commission errors in the
SST as a function of time after alcohol and THC administration in
every treatment condition
Fig. 4 Mean (SE) tracking error, control losses, correct detections, and reaction time during the DAT as a function of time after alcohol and THC
administration in every treatment conditions
398 Psychopharmacology (2011) 214:391–401correct signal detections. Number of times that subjects lost
control over the primary task (tracking) during this dual task
performance appeared particularly sensitive to the impairing
effect of THC. During alcohol placebo, mean number of
control losses were always low, independent of THC
administration. During treatments with low and high ethanol
doses, mean number of control losses increased by a factor
two and five, respectively, after smoking a THC cigarette.
Univariate analysis indeed revealed a significant alcohol×
THC interaction for this particular parameter, supporting the
notionthatthe combination ofalcohol and THC detrimentally
affected the number of control losses in a synergistic manner.
THC effects on reaction time and signal detection in the
divided-attention task may have also been related to
concomitant alcohol use. The latter measures did not reveal
an alcohol×THC interaction, but an additive effect of
alcohol and THC cannot be excluded. Previous studies
demonstrated that the divided-attention task is very sensi-
tive to the effects of THC and alcohol alone when given to
occasional cannabis users or healthy volunteers (Moskowitz
1984; Ramaekers et al. 2009; Schulte et al. 2001). Other
studies have demonstrated that low doses of THC and
alcohol that do not affect psychomotor function when given
alone may still impair performance when given in combi-
nation (Lamers and Ramaekers 2001). In other words, small
THC impairments that would go unnoticed in isolation still
might exceed the (statistical) threshold of detection when
added to the impairment produced by concurrent alcohol.
Likewise, it is conceivable that negligible THC effects on
divided attention as previously demonstrated in heavy
cannabis users (Ramaekers et al. 2009) may become more
apparent when added to those of a social dose of alcohol.
This might particularly be true for attention tasks that are
known for their very high sensitivity to drug and alcohol
effects (Moskowitz 1984).
Data from the present study confirmed that chronic
cannabis users develop tolerance to the behaviorally
impairing effects of THC. However, previous notions
(Marks and MacAvoy 1989; Wright and Terry 2002) that
chronic cannabis use would also develop cross-tolerance for
the impairing effects of alcohol were not confirmed. It
should be noted however that previous studies never
demonstrated complete tolerance to the behaviorally
impairing effects of alcohol in heavy cannabis users.
Generally, they showed that heavy cannabis users were
less impaired after an alcohol challenge than non-drug users
or infrequent cannabis users. Moreover, such demonstra-
tions of partial tolerance were always very selective for
single performance parameters (e.g., tracking accuracy),
whereas other task parameters (e.g., reaction time) did not
reveal cross-tolerance. Previous demonstrations of cross-
tolerance were obtained after administration of single doses
of alcohol. Performance testing occurred during the
descending phase of the blood alcohol curve. Consequently,
BACs were generally lower than those obtained in the
present study after repeated alcohol dosing. For example,
Wright and Terry (2002) tested tracking performance of
heavy cannabis users within 30 min after drinking while
mean BACs declined from 0.28 to 0.22 mg/ml. Mean BAC
levels in the present study however were two to three times
as high and experimentally controlled to achieve relatively
steady state levels during 5 h of repeated performance
testing. Repeated alcohol challenges and high BAC levels
thus may have provoked more pronounced alcohol impair-
ments than can be observed after single administration of a
low alcohol dose. Consequently, cross-tolerance or behav-
ioral adaptation may have been lacking or insufficient to
compensate for prolonged alcohol impairments as observed
in the present study.
The general lack of cross-tolerance for the impairing
effects of alcohol as well as the potential of ethanol to
potentiate the effects of THC in the divided-attention task
may have important implications for heavy cannabis users
who drive under the influence of both drugs. Heavy
cannabis users usually operate their vehicle on day to day
basis because they believe they developed resistance
against the impairing effect of THC (Ramaekers et al.
2009). In the present study, most participants (79%)
admitted to driving under the influence of cannabis and a
substantial proportion (32%) also admitted to driving under
the influence of cannabis and alcohol in combination. The
present data however demonstrated that mean BAC
concentrations up to 0.7 mg/ml produce significant perfor-
mance impairment and that the presence of alcohol may
potentiate detrimental effects of THC during dual task
performances that are common during car driving. Additive
and synergistic effects of alcohol and THC on driving
performance have previously been shown in occasional
cannabis users (O'Kane et al. 2002; Ramaekers et al. 2004;
Sewell et al. 2009). The present study demonstrates that
additive and synergistic effects of THC and alcohol on
performance can pertain to heavy cannabis users as well.
In conclusion, the present study generally confirms that
heavy cannabis users develop tolerance to the impairing
effects of THC on neurocognitive task performance. Yet,
heavy cannabis users did not develop cross-tolerance to the
impairing effects of alcohol, and the presence of the latter
even selectively potentiated THC effects on measures of
divided attention.
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